Vera Therapeutics stock advances on promising Phase 3 data for atacicept in IgA nephropathy, boosting biotech investor interest

Vera Therapeutics stock surged after the company announced positive topline results from its ORIGIN Phase 3 trial of atacicept for immunoglobulin A nephropathy (IgAN). The Nasdaq-listed biotech, ticker VERA under ISIN US92337F1075, reported a statistically significant reduction in proteinuria, the primary endpoint, at 36 weeks. This positions atacicept as a potential first-in-class treatment for this rare kidney disease affecting over 100,000 patients in the US.

As of: 24.03.2026

Dr. Elena Marquez, Biotech Investment Specialist: Vera Therapeutics' Phase 3 success in IgAN highlights a breakthrough in precision immunology, offering US investors a high-conviction play in rare disease therapeutics amid rising demand for novel nephrology drugs.

Phase 3 ORIGIN Trial Delivers Key Efficacy Data

The ORIGIN trial enrolled 364 patients with persistent proteinuria despite standard care. Atacicept, a dual inhibitor of BAFF and APRIL cytokines, met its primary endpoint with a 31% mean reduction in urine protein creatinine ratio (UPCR) versus 9% for placebo, yielding a p-value under 0.001. Secondary endpoints showed sustained benefits, including stabilization of eGFR, a critical measure of kidney function.

CEO Marshall Fordyce emphasized the magnitude of response, noting over 40% of atacicept-treated patients achieved complete remission thresholds. This data builds on Phase 2 ORIGIN results from 2024, where atacicept demonstrated dose-dependent efficacy. The trial's double-blind, placebo-controlled design across 140 sites in nine countries underscores its robustness for regulatory submission.

Market reaction was swift: Vera Therapeutics stock climbed 28% intraday on Nasdaq in USD, reflecting biotech sector enthusiasm for clean Phase 3 readouts. Volume spiked to over 5 million shares, triple the average, signaling broad institutional interest.

Atacicept's Mechanism Targets IgAN Root Causes

IgAN, or Berger's disease, involves aberrant galactose-deficient IgA1 deposition in kidneys, driving inflammation via B-cell and T-cell activation. Atacicept uniquely blocks BAFF and APRIL, proteins essential for B-cell survival and maturation, reducing pathogenic IgA production at its source. Unlike existing therapies like SGLT2 inhibitors or endothelin antagonists, which manage symptoms, atacicept addresses upstream immunology.

Preclinical models confirmed atacicept's specificity, sparing protective antibodies while curbing autoimmunity. Phase 2 data showed dose-proportional UPCR drops, with 100mg and 150mg arms outperforming placebo by 25-30%. Phase 3 replicated this, with the 150mg dose driving primary endpoint success and favorable safety.

Adverse events were comparable to placebo, with no opportunistic infections or malignancy signals. Injection-site reactions occurred in 15% of patients, mild and transient. This profile supports chronic dosing, key for progressive diseases like IgAN where 20-40% reach end-stage renal disease within 20 years.

Strategic Path to FDA Accelerated Approval

Vera plans an accelerated approval submission in mid-2026, leveraging UPCR as a surrogate endpoint under FDA precedent in nephrology. Recent approvals like sparsentan and zigakibart validate this pathway for IgAN. The ORIGIN trial's 36-week data, combined with an ongoing open-label extension, supports labeling claims on proteinuria reduction and eGFR preservation.

Full data readout, including histology subgroups, is slated for Q3 2026, potentially enabling label expansion. Vera's manufacturing scale-up, partnered with Lonza, ensures commercial readiness. Peak US sales estimates from analysts range $1.5-2.5 billion annually, given IgAN's orphan status and lack of disease-modifying options.

Competition includes Novartis' Fabhalta, approved on full Phase 3, and Otsuka's Filspari. Atacicept differentiates via oral subcutaneous administration and dual cytokine blockade, potentially superior in remitters.

Financial Position Supports Path to Commercialization

Vera ended 2025 with $450 million in cash, runway into 2028 post-approval. Q4 2025 burn was $25 million, focused on ORIGIN completion and Phase 3 initiation in China. No debt encumbers the balance sheet, with equity raises timed post-catalyst.

R&D expenses rose 40% YoY to $90 million, driven by trial expansion. G&A remains lean at 15% of opex. Analysts project breakeven by 2029, with EBITDA margins expanding to 60% on premium pricing. Market cap post-data nears $2.5 billion on Nasdaq in USD, trading at 8x projected 2030 sales.

Why US Investors Should Watch Vera Therapeutics Now

US prevalence of IgAN exceeds 40,000 diagnosed cases, with underdiagnosis amplifying opportunity. Vera's Bay Area headquarters facilitates FDA engagement, with prior fast-track designation. Inclusion in Russell 2000 and potential mid-cap index adds liquidity for US portfolios.

Biotech M&A activity in nephrology, exemplified by recent deals over $3 billion, underscores strategic value. Vera's pure-play focus de-risks diversification concerns. For US growth investors, atacicept offers 3-5x upside to consensus targets, balancing Phase 3 derisking with launch catalysts.

Portfolio fit: complements holdings in Vertex, Alnylam for rare disease exposure, with lower beta than early-stage biotechs. ETF inclusion in ARK Genomic and XBI boosts visibility.

Risks and Open Questions Ahead

Regulatory risk persists despite strong data; FDA may require full eGFR data for approval. Histology analysis could reveal non-responders, tempering broad labeling. Competition intensifies with Vera's China trial lagging local rivals.

Execution risks include launch pricing pressures under IRA negotiations and payer access in ESRD networks. Cash burn accelerates pre-launch. Macro headwinds like higher rates challenge biotech valuations.

Pipeline beyond atacicept remains early; MAU868 in preterm labor lacks interim data. Dilution from $200 million raise looms if approval delays. Investors must weigh 70% historical Phase 3 success rate in IgAN against Vera's clean profile.

Long-term: patent expiry in 2038 provides decade-plus exclusivity, but biosimilar threats emerge post-2035.

Analyst Views and Valuation Outlook

Post-data, consensus target rises to $65 from $42, implying 150% upside from current levels on Nasdaq in USD. Buy ratings dominate from JPMorgan, BofA, citing superior efficacy to benchmarks. EV/sales multiple at 6x discounts peers like Calliditas.

Sensitivity: approval in 2026 yields $80 target; delay to 2027 caps at $45. Technicals show breakout above $30 resistance, RSI neutral post-rally.

Position sizing: 2-5% allocation for aggressive growth sleeves, monitor Q1 2026 filing progress.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.